Table 3.
Associations between patient and tumor characteristics and FGFR1 expression in tumor-adjacent and tumor tissues.
| All | Tumor-adjacent tissue (IHC) | Tumor tissue (IHC) | |||
|---|---|---|---|---|---|
| n=426 | OR (95% CI) a | OR (95% CI) b | OR (95% CI) a | OR (95% CI) b | |
| PATIENT CHARACTERISTICS | |||||
| Age at diagnosis | |||||
| ≤50 years (premenopausal) | 78 (18) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| >50 years (postmenopausal) | 348 (82) | 2.53 (1.02–6.26) | 8.00 (2.47–25.86) | 0.84 (0.40–1.78) | 1.08 (0.36–3.28) |
| BMI at time of diagnosis, kg/m2 | |||||
| <25.0 | 220 (52) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| ≥25.0 | 206 (48) | 1.24 (0.68–2.28) | 1.26 (0.69–2.32) | 0.67 (0.36–1.24) | 0.66 (0.36–1.23) |
| BI-RADS category for breast density | |||||
| A+B (low density) | 178 (42) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| C+D (high density) | 243 (57) | 0.73 (0.40–1.34) | 0.68 (0.36–1.30) | 1.39 (0.74–2.60) | 1.34 (0.70–2.60) |
| TUMOR CHARACTERISTICS | |||||
| Tumor size | |||||
| ≤20 mm (T1) | 332 (78) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| ≥21mm (T2+) | 93 (22) | 0.76 (0.35–1.67) | 0.78 (0.35–1.72) | 0.96 (0.46–2.01) | 0.93 (0.44–1.96) |
| Nodal status | |||||
| Negative (N0) | 306 (72) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| Positive (N1+) | 120 (28) | 1.06 (0.54–2.06) | 1.08 (0.55–2.11) | 0.89 (0.45–1.75) | 0.86 (0.44–1.70) |
| Histological grade | |||||
| 1 + 2 | 291 (69) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| 3 | 133 (31) | 0.73 (0.36–1.45) | 0.75 (0.37–1.51) | 1.86 (1.00–3.44) | 1.83 (0.98–3.40) |
| Ki67 status | |||||
| Low + intermediate | 253 (60) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| High | 172 (40) | 0.61 (0.32–1.16) | 0.62 (0.32–1.21) | 2.18 (1.18–4.02) | 2.09 (1.13–3.88) |
| ER status | |||||
| Positive | 381 (90) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| Negative | 44 (10) | 0.32 (0.07–1.41) | 0.33 (0.08–1.46) | 1.26 (0.50–3.16) | 1.26 (0.50–3.18) |
| PR status | |||||
| Positive | 314 (74) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| Negative | 111 (26) | 0.38 (0.16–0.95) | 0.39 (0.16–0.98) | 1.50 (0.78–2.85) | 1.49 (0.78–2.86) |
| HER2 status | |||||
| Negative | 384 (90) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| Positive | 41 (10) | 1.23 (0.47–3.22) | 1.26 (0.48–3.35) | 1.38 (0.55–3.49) | 1.29 (0.51–3.28) |
| SURROGATE SUBTYPES (IHC) | |||||
| Luminal A-like | 232 (54) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| Luminal B-like | 123 (29) | 0.78 (0.38–1.59) | 0.81 (0.39–1.69) | 2.56 (1.29–5.06) | 2.49 (1.25–4.98) |
| HER2-positive | 41 (10) | 1.04 (0.39–2.80) | 1.07 (0.39–2.93) | 2.13 (0.78–5.78) | 1.99 (0.73–5.46) |
| Triple-negative (TNBC) | 30 (7) | – | – | 1.86 (0.59–5.94) | 1.90 (0.59–6.10) |
| MOLECULAR INTRINSIC SUBTYPES (RNAseq) | |||||
| Luminal A | 201 (61) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| Luminal B | 61 (19) | 0.88 (0.35–2.22) | 0.84 (0.33–2.14) | 1.64 (0.67–4.00) | 1.75 (0.71–4.33) |
| HER2-enriched | 38 (12) | – | – | 1.67 (0.57–4.83) | 1.56 (0.53–4.60) |
| Basal-like | 28 (8) | – | – | 2.32 (0.78–6.87) | 2.35 (0.78–7.04) |
a
Crude model.
b
Model adjusted for age at diagnosis and number of years the samples were stored.
Values in bold indicate p<0.05.